Meta-Analysis Comparing Dual Antiplatelet Therapy Versus Single Antiplatelet Therapy Following Transcatheter Aortic...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Current guidelines recommend dual antiplatelet therapy (DAPT) post-transcatheter aortic valve implantation (TAVI).
• Emerging evidence suggests DAPT may increase bleeding events without clear clinical benefit.

Purpose of the Study:

• To compare the efficacy and safety of DAPT versus single antiplatelet therapy (SAPT) after TAVI.
• To evaluate rates of ischemic stroke, myocardial infarction, bleeding, and death.

Main Methods:

• Meta-analysis of 3 randomized and 4 non-randomized studies comparing DAPT and SAPT in TAVI patients.
• Used Mantel-Haenszel random effects model for odds ratios (OR) and 95% confidence intervals (CI).
• Assessed outcomes at 30 days and 6-12 months follow-up.

Main Results:

• DAPT significantly increased life-threatening bleeding (LTB) and significant bleeding rates at 30 days.
• Significant bleeding remained higher with DAPT at 6-12 months, with a non-significant trend for LTB.
• No significant differences were observed in mortality, ischemic stroke, or myocardial infarction between DAPT and SAPT groups.

Conclusions:

• Dual antiplatelet therapy (DAPT) after TAVI is associated with increased bleeding risk.
• DAPT does not provide additional benefits in reducing ischemic events or mortality compared to SAPT post-TAVI.
• Single antiplatelet therapy (SAPT) appears to be a safer and equally effective strategy after TAVI.